Radius Health, Inc. (NASDAQ:RDUS) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by $0.23, Briefing.com reports. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same quarter last year, the business posted ($1.01) EPS.

Radius Health (RDUS) traded down 2.99% on Friday, reaching $41.79. 827,700 shares of the company’s stock were exchanged. Radius Health has a 52 week low of $31.58 and a 52 week high of $59.88. The company’s market cap is $1.81 billion. The stock’s 50 day moving average is $44.24 and its 200 day moving average is $40.59.

TRADEMARK VIOLATION WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/05/radius-health-inc-rdus-issues-quarterly-earnings-results-misses-estimates-by-0-23-eps.html.

Several research analysts recently issued reports on the stock. BidaskClub upgraded shares of Radius Health from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. ValuEngine upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday, July 17th. Finally, Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $55.67.

In other news, major shareholder Growth N. V. Biotech purchased 15,000 shares of Radius Health stock in a transaction dated Friday, May 12th. The shares were bought at an average cost of $34.00 per share, for a total transaction of $510,000.00. Following the completion of the acquisition, the insider now owns 4,873,799 shares in the company, valued at approximately $165,709,166. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of Radius Health stock in a transaction dated Tuesday, May 9th. The shares were purchased at an average price of $35.93 per share, for a total transaction of $1,796,500.00. Following the completion of the acquisition, the insider now owns 4,858,799 shares of the company’s stock, valued at approximately $174,576,648.07. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 273,400 shares of company stock worth $9,559,538. Company insiders own 15.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in RDUS. Blair William & Co. IL purchased a new stake in Radius Health during the second quarter valued at $205,000. BNP Paribas Arbitrage SA boosted its stake in Radius Health by 43.4% in the second quarter. BNP Paribas Arbitrage SA now owns 6,916 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 2,093 shares during the period. Legal & General Group Plc boosted its stake in Radius Health by 14.5% in the second quarter. Legal & General Group Plc now owns 13,372 shares of the biopharmaceutical company’s stock valued at $605,000 after buying an additional 1,697 shares during the period. Bank of New York Mellon Corp boosted its stake in Radius Health by 19.3% in the second quarter. Bank of New York Mellon Corp now owns 529,865 shares of the biopharmaceutical company’s stock valued at $23,965,000 after buying an additional 85,816 shares during the period. Finally, SG Americas Securities LLC boosted its stake in Radius Health by 22.9% in the second quarter. SG Americas Securities LLC now owns 8,936 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 1,664 shares during the period. Institutional investors own 99.50% of the company’s stock.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Earnings History for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.